Immatics N.v. · NASDAQ:IMTX
Immatics — Technical Presentation (October 2026)
29 slides from Immatics's technical presentation, Oct 26, 2026
Slide 1: Initial Results With IMA402, a PRAME-Targeted TCER in Advanced Solid Tumors
Initial Results With IMA402, a PRAME - Targeted T - cell Receptor (TCR) - based Bispecific T - cell Engager (TCER) in Advanced Solid Tumors Dirk Schadendorf 1 , Jessica C. Hassel 2 , Philipp Harter 3 , Ralf Gutzmer 4 , Mathilde Jalving 5 , Lisa Zimmer 6 , Yenny Angela 4 , Daniel Heudobler 7 , Freder
Slide 2: Declaration of Interests
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 2 Declaration of Interests Advisory board, consulting, speaker’s honoraria: AstraZeneca, BioAlta , BioNTech, BMS, Boehringer Ingelheim, Daiichi Sankyo, EeBeTe , Formycon , ImCheck , Immat
Slide 3: IMA402 is an Optimized T-cell Engager Designed to Target PRAME
3 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Indication Cutaneous Melanoma Endometrioid Endometrial Carcinoma Uterine Carcinosarcoma Synovial Sarcoma Acral Melanoma Uveal Melanoma Mucosal Melanoma Endometrial Clear Cell Carcinoma
Slide 4: IMA402 - Study Design
4 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. IMA402 - 101 Study Design Prof. Dr. Dirk Schadendorf ; Abstract #8465 EudraCT No. 2022 - 503133 - 54 - 00; NCT05958121. a Cutaneous melanoma, melanoma of unknown primary, uveal melanoma
Slide 5: Demographics: Heavily Pretreated Patient Population
5 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Demographics: Heavily Pretreated Patient Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibitor; LDH, lactate
Slide 6: Safety Profile Across All Indications and Dose Levels
6 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety Profile Across All Indications and Dose Levels (N=126) Prof. Dr. Dirk Schadendorf ; Abstract #8465 a TRAEs: All treatment - emergent adverse events at least possibly related to I
Slide 7: Efficacy of IMA402 ± Pembrolizumab Across All Indications
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 7 Efficacy of IMA402 “ Pembrolizumab Across All Indications in the Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Includes cutaneous melanoma and 1 patient with uveal m
Slide 8: Exploratory Analysis of PRAME Levels and Disease Outcome
8 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Exploratory Analysis of PRAME Levels and Disease Outcome in Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a PRAME low does not preclude response to IMA402, 1 cPR obser
Slide 9: Patient Disposition by PRAME Level in Efficacy Population
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 9 Efficacy Population n=40 PRAME low n=9 a PRAME high n=31 Melanoma n=22 IMA402 Monotherapy n=20 IMA402 + Pembrolizumab n=2 Ovarian Cancer n=6 Other b n=3 Patient Disposition Prof. Dr. Di
Slide 10: Efficacy of IMA402 ± Pembrolizumab by PRAME Expression
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 10 Efficacy of IMA402 “ Pembrolizumab by PRAME Expression Prof. Dr. Dirk Schadendorf ; Abstract #8465 PRAME low (n=9) PRAME high (n=31) IMA402 monotherapy IMA402 + pembrolizumab Melanoma
Slide 11: Durability of Responses in PRAME high Melanoma
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 11 Durability of Responses in PRAME high Melanoma Prof. Dr. Dirk Schadendorf ; Abstract #8465 Ongoing patients were censored at the data cutoff for OS; OS rates were calculated using the
Slide 12: Key Takeaways
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 12 Key Takeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets acce
Slide 13: Thank You – Trial Participants & Caregivers
Thank You – Trial Participants & Caregivers University Hospital Würzburg University Medical Center Utrecht Marien Hospital Düsseldorf Mühlenkreiskliniken Minden Klinikum Chemnitz Ev. Kliniken Essen - Mitte NCT Heidelberg University Hospital Regensburg University Medical Center Groningen Nuremberg Ge
Slide 14: Appendix
APPENDIX Prof. Dr. Dirk Schadendorf ; Abstract #8465
Slide 15: Patient Disposition
Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. 15 Patient Disposition Prof. Dr. Dirk Schadendorf ; Abstract #8465 Data cutoff Jun 1, 2026 Safety Population N=126 Safety Population RP2D Range, PRAME+ n=48 Efficacy Population a n=40 PRA
Slide 16: Demographics in PRAME high Melanoma
16 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Demographics in PRAME high Melanoma Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Excludes patients with uveal melanoma due to different staging guidelines. n=1 below RP2D range missin
Slide 17: Safety Profile of IMA402 Monotherapy and IMA402 + Pembrolizumab
17 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety Profile of IMA402 Monotherapy and IMA402 + Pembrolizumab Prof. Dr. Dirk Schadendorf ; Abstract #8465 Data cutoff Jun 1, 2026 IMA402 Monotherapy (n=107) No additive toxicity was
Slide 18: Safety Profile of the Efficacy Population
18 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Safety Profile of the Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 IMA402 Efficacy Population ± Pembrolizumab (n=40) a TRAEs: All treatment - emergent adverse events
Slide 19: CRS Dynamics
19 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. CRS Dynamics Prof. Dr. Dirk Schadendorf ; Abstract #8465 • Favorable CRS profile with no > G2 CRS after first step dose • Median CRS onset from first IMA402 infusion in days (range) c
Slide 20: Durability of IMA402 ± Pembrolizumab Across All Indications
20 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Durability of IMA402 “ Pembrolizumab Across All Indications in Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 BOR, best overall response; BL, baseline; cCR , confirmed
Slide 21: Responses to IMA402 ± Pembrolizumab in PRAME high Melanoma
21 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Responses to IMA402 “ Pembrolizumab in PRAME high Melanoma Prof. Dr. Dirk Schadendorf ; Abstract #8465 BOR, best overall response; BL, baseline; cCR , confirmed complete response; cORR
Slide 22: Promising Initial Survival Data (PFS, iPFS, OS)
22 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. a iRECIST , developed by the RECIST Working Group, adapts RECIST 1.1 definition for progression for immunotherapies by introducing unco nfi rmed ( iUPD ) and confirmed ( iCPD ) progres
Slide 23: PRAME Prevalences in Selected Indications
23 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. PRAME Prevalences in Selected Indications Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Data on file: PRAME target prevalence is based on TCGA RNAseq analysis using proprietary mass sp
Slide 24: Outlook: Liquid Biopsy for Patient Selection
24 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Outlook: Liquid Biopsy for Patient Selection Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Non - responder: PD, SD. Responder: PR, cPR , cCR . # Mann - Whitney U test cCR , confirmed c
Slide 25: Outlook: Decitabine as Potential PRAME Enhancer for Combination with IMA402
25 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Outlook: Decitabine as Potential PRAME Enhancer for Combination with IMA402 Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Data on file. SCC25: epithelial - like squamous cell carcinoma
Slide 26: Clinical Responses in PRAME high Efficacy Population
26 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. b Bridging therapy. BOR, best overall response;
Slide 27: Clinical Responses in PRAME high Efficacy Population
27 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. b Bridging therapy. BOR, best overall response;
Slide 28: Clinical Responses in PRAME high Efficacy Population
28 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. BOR, best overall response; PFS, progression -
Slide 29: Clinical Responses in PRAME high Efficacy Population
29 Content of this presentation is copyright and responsibility of the author. Permission is required for re - use. Clinical Responses in PRAME high Efficacy Population Prof. Dr. Dirk Schadendorf ; Abstract #8465 a Median target lesion sum of diameter. BOR, best overall response; PFS, progression -